Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 8/20 | 0.84 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.84 |
| ▸ | RET | P07949 | 1/20 | 0.84 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.84 |
| ▸ | MARK3 | P27448 | 1/20 | 0.84 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.84 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.84 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.84 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.84 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.84 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.84 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.84 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.84 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.84 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.84 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.84 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.84 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.84 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.84 |
| ▸ | FGFR2 | P21802 | 13/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fexagratinib SCHEMBL15250892 | 0.91 | FGFR1 (1.00) | FGFR1NTRK1RETPDGFRBMARK3 | |
| Fexagratinib SCHEMBL29479542 | 0.91 | FGFR1 (1.00) | FGFR1NTRK1RETPDGFRBMARK3 | |
| Azd-4547 SCHEMBL22132858 | 0.91 | FGFR1 (1.00) | FGFR1NTRK1RETPDGFRBMARK3 | |
| Azd-4547 SCHEMBL15433983 | 0.91 | FGFR1 (1.00) | FGFR1NTRK1RETPDGFRBMARK3 | |
| SCHEMBL62562 | 0.90 | FGFR1 (0.82) | FGFR1NTRK1RETPDGFRBMARK3 | |
| SCHEMBL63830 | 0.87 | FGFR1 (0.77) | FGFR1NTRK1RETPDGFRBMARK3 | |
| SCHEMBL13574146 | 0.87 | FGFR1 (0.77) | FGFR1NTRK1RETPDGFRBMARK3 | |
| SCHEMBL13574162 | 0.87 | FGFR1 (0.77) | FGFR1NTRK1RETPDGFRBMARK3 | |
| SCHEMBL62894 | 0.86 | FGFR1 (0.76) | FGFR1NTRK1RETPDGFRBMARK3 | |
| SCHEMBL22651509 | 0.86 | FGFR1 (0.90) | FGFR1NTRK1RETPDGFRBMARK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771698-B2 | Methods of treating cholangiocarcinoma | FOUNDATION MEDICINE, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20170304313-A1 | Therapeutic Combination For The Treatment Of Cancer | NOVARTIS AG (CH) | 2017-10-26 | — | — | US | disclosed |
| US-20160095842-A1 | COMBINATION THERAPY CONTAINING A PI3K-ALPHA INHIBITOR AND FGFR KINASE INHIBITOR FOR TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2016-04-07 | — | — | US | disclosed |
| US-20150051210-A1 | Tyrosine Kinase Inhibitor Combinations and their Use | NOVARTIS AG (CH) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051210-A1 | Tyrosine Kinase Inhibitor Combinations and their Use | MET, FGFR3, FGFR1 | FGFR1 3/4885NTRK1 106/4885RET 6/4885 |
| US-20160095842-A1 | COMBINATION THERAPY CONTAINING A PI3K-ALPHA INHIBITOR AND FGFR KINASE INHIBITOR FOR TREATING CANCER | FGFR3, FGFR1, PIK3CA | FGFR1 2/4885NTRK1 1716/4885RET 62/4885 |
| US-20170304313-A1 | Therapeutic Combination For The Treatment Of Cancer | FGFR3, EGFR, FGFR2 | FGFR1 7/4885NTRK1 375/4885RET 22/4885 |
| US-11771698-B2 | Methods of treating cholangiocarcinoma | HCCS, PNLIP, LIPA | FGFR1 1732/4885NTRK1 2894/4885RET 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.